Field-Practical Automated Battery for Assessing and Monitoring Cognitive
Agency / Branch:
DOD / OSD
OmniSite BioDiagnostics Inc. (OmniSite) proposes to aid in the field diagnosis of soft tissue injuries of DOD troops by development of DNA aptamer-based assays for protein markers and hydroxylated amino acids in diluted whole blood. DNA aptamers arenovel, inexpensive replacement reagents for antibodies that do not require animal hosts for production and are therefore inexpensive and simple to produce. In phase I, OmniSite will focus its assay development efforts on skeletal Troponin I (sTnI),creatine kinase isoform MM1 (CK-MM1), carbonic anhydrase III (CA III), hydroxylysine and hydroxyproline. This panel of candidate markers for soft tissue injury will be simultaneously analyzed in OmniSite's partitioned microfluidic cartridge byfluorescence polarization (FP). FP provides rapid, highly sensitive and accurate one-step binding assays without the need for wash steps. OmniSite has an intellectual property position, which allows miniaturization of FP into an inexpensive handheldreader format. The fusion of these powerful technologies will provide the DOD with facile and reliable field assays for soft tissue injuries. In Phase II, OmniSite will sequence the DNA aptamers, refine the FP-aptamer assays and deliver an FP readerprototype with model assays for testing. If successful, OmniSite will have an assay system that numerous point-of-care facilities may desire to aid in diagnosis of soft tissue injuries or cardiac infarctions for the general public.
Small Business Information at Submission:
Chief Technical Officer
OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street, Suite 200 Austin, TX 78701
Number of Employees: